# A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

> **NCT05955586** · PHASE1 · COMPLETED · sponsor: **Spero Therapeutics** · enrollment: 33 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** SPR720

## Key facts

- **NCT ID:** NCT05955586
- **Lead sponsor:** Spero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-02-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955586, "A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05955586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*